Oculus Innovative Sciences Completes Enrollment Of Phase II Trial Of Microcyn(R) Technology In Treatment Of Mildly Infected Diabetic Foot Ulcers

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced completion of enrollment of its Phase II clinical trial of Microcyn® Technology. The company has enrolled and randomized 67 patients in its open-label Phase II clinical trial evaluating its Microcyn Technology in the treatment of mildly infected diabetic foot ulcers. The study, which is being conducted at 15 U.S. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 9th, 2007